Selective Stromal Melanin Modulation (SSMM): the biophysical and clinical framework for response-guided controlled pigment release within Lumineyes™

Mustafa Mete, MD
MyLumineyes Research, Istanbul, Türkiye
Corresponding author: Mustafa Mete, MD — info@mylumineyes.com
ORCID: 0009-0004-3128-2853

Abstract

Purpose: To define and defend the mechanistic and clinical rationale for Selective Stromal Melanin Modulation (SSMM), the scientific foundation of the Lumineyes™ response-guided controlled pigment-release methodology. SSMM deliberately targets anterior stromal melanin and treats staged release, the eye's biological response, and re-exposure decisions as one integrated process, with preservation of non-target ocular structures as an explicit design objective.

Methods: A critical narrative synthesis integrates ocular pigment biology, selective laser–tissue interaction, experimental iris studies, pigment-associated trabecular physiology, immunocellular outflow mechanisms, clinical reports, and the author-developed Lumineyes research architecture. The nine-year Lumineyes™ clinical archive is considered separately as physician-recorded observational evidence, not as a newly analyzed comparative cohort. Evidence sources were reviewed through 23 November 2026.

Results: Five convergent arguments support the SSMM architecture. First, melanin is an optically preferential target, and experimental anterior iris pigment modification can occur without detectable alteration of the posterior pigment epithelium under the tested conditions [5, 8]. Second, pigment liberation is an intended procedural response; staged exposure permits reassessment before further release-generating treatment rather than automatic cumulative exposure [14, 25, 44]. Third, L-SAFE links subsequent treatment decisions to pressure, inflammation, corneal/endothelial status, angle/outflow findings and visual function [25]. Fourth, experimental pigment loading can increase outflow resistance, while distinct monocyte-associated mechanisms can increase outflow facility, justifying a biologically bidirectional SSMM–IOP model [19, 28, 33, 41–43]. Fifth, the author's 2017–2026 clinical archive records approximately 1,500 treated patients, more than 3,000 eyes, a 97.4% clinic-assessed pigment-response measure, approximately 15 transient early pressure elevations, and no documented progressive pressure elevation or treatment-associated permanent visual loss within the available records [46]. These observations support the clinical provenance of the response-guided approach but are not a controlled comparative safety estimate.

Conclusion: SSMM presents a positive, evidence-linked rationale for deliberate, response-guided controlled pigment release within Lumineyes™: preferential stromal targeting, staged modulation,

active ocular-state assessment, and individualized continuation decisions act as one therapeutic architecture. The aim is an effective pigmentary response with protection-oriented management of the anterior segment, not pigment elimination at any cost. Experimental data and longitudinal clinical experience support the plausibility and clinical relevance of this architecture; prospective comparisons, quantitative tissue outcomes and direct outflow studies remain appropriate next steps.

Keywords: selective stromal melanin modulation; Lumineyes; response-guided treatment; controlled pigment release; anterior iris stroma; L-SAFE; P-CLEAR; pigment processing; aqueous outflow; intraocular pressure

Introduction

Human iris coloration is determined by the quantity and spatial organization of melanin, stromal architecture, optical absorption, and scattering. Morphological studies associate visible color differences more closely with the amount and distribution of stromal pigment than with melanocyte counts alone [1, 2]. The iris is also a functional tissue comprising melanocytes, fibroblasts, vascular and neural elements, and extracellular matrix; an intervention directed at pigment cannot be interpreted exclusively as a color intervention [3, 4].

The scientific claim of SSMM is that the method of producing a pigmentary response matters as much as the appearance of the response itself. Lumineyes™ therefore does not define procedural success as maximal immediate pigment ablation. SSMM deliberately engages anterior stromal melanin, seeks controlled release across clinically reassessed stages, and uses the observed ocular response to govern further intervention. This is an intervention architecture with a specified target, expected release event, monitoring domains and decision logic—not simply a request that others investigate pigment behavior [12, 14, 25, 44].

The principle of selective photothermolysis provides a starting point for assessing preferential interaction with an absorbing chromophore [5]. Optical behavior additionally depends on wavelength, pulse duration, delivered energy and fluence, beam geometry, optical scattering, and local tissue composition [6]. Photothermal and photomechanical pathways can coexist, and selectivity cannot be inferred from melanin absorption alone [7].

Published work includes controlled rabbit iris experiments [8], a human clinical series with staged photoablative iridoplasty [9], and broader reviews of cosmetic eye-color interventions [10, 11]. These sources differ in exposure, design, follow-up, and ascertainment of outcomes. Importantly, severe secondary pigmentary glaucoma has also been documented after cosmetic iris laser treatment [18, 27]. Shared cosmetic intent does not establish equivalence of protocols, nor does protocol heterogeneity invalidate documented serious complications.

A generic laser iris depigmentation label is a procedural category, not a scientifically adequate definition of SSMM. Two exposures producing similar visible lightening may differ in pigment mobilization, stromal effects, recovery dynamics and consequences for the angle and outflow pathway. The Lumineyes™ distinction is the explicit integration of selective stromal interaction, staged release-generating treatment and response-conditioned continuation. These are substantive clinical-control variables, not interchangeable branding terms [14, 25, 44].

Review approach, scope, and scientific background

Literature identification and selection. This targeted, non-systematic narrative synthesis considered foundational and PubMed/MEDLINE-indexed literature identified through 23 November 2026. Search themes combined iris stroma, pigment, melanocytes, laser iris depigmentation, photoablative iridoplasty, inflammation, pigment dispersion, secondary glaucoma, trabecular meshwork, macrophages, aqueous outflow, and longitudinal prediction or sequential decision methods. Reference tracking and an independent source-to-claim audit informed the updated selection; this was not a systematic review, meta-analysis, or exhaustive search. Studies were retained according to anatomical and mechanistic relevance, including adverse and null evidence, rather than agreement with SSMM [30].

Evidence classification. Human histological and cellular studies establish anatomical or cellular facts; controlled experimental studies demonstrate responses only under their tested conditions; clinical series describe outcomes within their own sampling and ascertainment methods; and case reports establish the possibility of serious events but cannot estimate incidence. Proposed SSMM constructs and the author's earlier Zenodo records document conceptual provenance rather than validation. Each evidentiary level is kept separate in the synthesis.

The Lumineyes™ methodology arose from exploratory work initiated in 2009 and a continuing physician-led clinical program from 2017 to 2026. Its development was driven by repeated direct observation of pigment response, recovery and anterior-segment physiology across successive treatment episodes. The associated SSMM, P-CLEAR, L-SAFE, LIPS, L-OAT, TRA, LRS and SSMM–IOP publications articulate different elements of one clinical and scientific program [12, 14, 20–22, 25, 43–46]. The present manuscript synthesizes that practice-derived rationale with independent experimental evidence; it does not reclassify the practice archive as a randomized or independently audited trial.

The core SSMM proposition has four inseparable determinants: the anterior stromal pigment selected for interaction; the release-generating laser exposure and its distribution across stages; the capacity of the eye and outflow pathway to tolerate and process the ensuing response; and the clinical decision to modify, delay or resume further treatment. L-SAFE formalizes the ocular-state assessment at the fourth determinant, while P-CLEAR articulates the second and third. SSMM–IOP describes one important physiological consequence of those interactions, not the entirety of the method [14, 25, 43, 44].

The analysis proceeds from optical target and physical exposure to pigment processing, cellular and physiological effects, repeated measurement, and decision assessment. Questions of safety, efficacy, and causal mechanism are posed as empirical endpoints rather than presumed consequences of the model.

Evidence hierarchy and inferential limits

This synthesis separates (a) human iris morphology and observation; (b) controlled animal or ex vivo iris exposure; (c) trabecular/retinal or non-iris mechanistic analogies; and (d) candidate SSMM-specific tests not yet performed. Cross-system transfer requires explicit attention to target compartment, optics, pulse and spot geometry, dose, tissue condition, particle load, medication, and

follow-up. An analogy may justify an experiment but cannot demonstrate exposure equivalence, safety, or treatment benefit.

The SSMM, LRS, LIPS, L-OAT, P-CLEAR, TRA and L-SAFE records document the author-developed research program, its terminology and proposed internal relationships. They are legitimate sources for the method's origin and clinical logic. Independent anatomical, experimental and physiological studies are used for their corresponding empirical findings; these two source types serve complementary purposes rather than being treated as substitutes for each other.

Operational Definition and Three Dimensions of Selectivity

SSMM is the biophysical and clinical framework underlying the Lumineyes™ response-guided controlled pigment-release method. Its intended initial event is preferential interaction with visible anterior stromal melanin; its intended downstream process includes pigment liberation and biological handling; its clinical control mechanism is staged exposure and response-conditioned continuation or withholding; and its anatomical objective is to minimize unintended effects on posterior iris pigment epithelium, stromal vasculature and architecture, corneal endothelium, the angle/outflow pathway and visual function [12, 14, 25, 44]. These are design principles and preservation objectives, not claims that every structure has been proven unaffected.

Within SSMM, "selective" describes preferential target interaction and avoidance of unnecessary deeper exposure; "controlled pigment release" means active control over exposure distribution, timing, reassessment and subsequent release-generating sessions, not direct real-time quantification of each liberated granule. "Response-guided" requires that the measured ocular state influence whether and when treatment continues. The approach deliberately retains pigment liberation as its intended mechanism, while treating the receiving anterior segment as a biologically active system [14, 44].

Three dimensions are operationally separated: biophysical selectivity asks whether target-associated absorption and physical response differ from suitable non-target comparators; anatomical selectivity asks whether secondary tissue alteration is spatially or quantitatively dissociable from pigment change; and functional selectivity examines ocular physiological outcomes after exposure. Evidence in one dimension cannot substitute for evidence in either of the others (Table 1).

Table 1. Three dimensions of selectivity within SSMM

Dimension	Scientific question	Measurement domain
Biophysical	Is interaction preferentially directed toward the intended pigment-bearing target?	Optical and laser–tissue measurements
Anatomical	Where do structural effects occur, and how do they evolve?	Structural imaging and anatomical assessment
Functional	How do relevant ocular functions behave following exposure?	Clinical and physiological assessment

Biophysical Foundations of Stromal Pigment Modification

Melanin and the local optical environment

Melanin is an endogenous ocular chromophore, but its response to optical radiation is conditional on absorption spectrum, pulse duration, irradiance, scattering, pigment localization, and surrounding tissue [4–7]. SSMM designates anterior stromal melanin-bearing structures as its intended region of study; it does not treat the iris as optically homogeneous.

The same gross iris color may conceal distinct pigment depth, density, and spatial heterogeneity. This suggests a testable phenotype–response relationship; appearance alone is an inadequate proxy for local optical dose or total released pigment.

Human iris stromal melanosomes also vary in chemical composition, not solely in visible pigment density. A study of dark-brown and blue-green irides identified markedly different eumelanin-to-pheomelanin ratios while reporting a shared eumelanin-rich outer surface [50]. This strengthens the LIPS/L-OAT premise that equal-looking regional pigment changes need not represent equal absorber chemistry. Whether repeated SSMM exposure alters melanosome surface chemistry or modifies subsequent laser responsiveness remains a specific inference—not an observed clinical mechanism.

Chromophore specificity cannot be defined by melanin alone. Ocular vessels and other absorbing or scattering structures contribute to local energy deposition and may mediate secondary tissue effects. Iris-directed frequency-doubled Nd:YAG exposure has been used to create anterior chamber inflammation in rabbits, illustrating that a 532-nm iris exposure can produce more than visible pigment change [31]. This study does not define a quantitative hazard threshold for a different optical configuration.

Localized pigment interaction

Both photothermal and photomechanical pathways are plausible during short-pulse exposure of pigmented tissues [7]. Microcavitation, if present, would require experiment-specific evidence regarding thresholds, bubble dynamics, and nearby stromal and endothelial effects. An observed color change cannot discriminate between these interactions. In human donor trabecular specimens, selective 532-nm trabeculoplasty produced comparatively limited ultrastructural damage relative to argon laser trabeculoplasty [32]. This establishes a contextual precedent for chromophore-preferential ophthalmic exposures, not a direct preservation claim for iris-directed SSMM.

Thermal confinement and stress confinement are distinct criteria determined by pulse duration relative to heat-diffusion and acoustic-transit times for the particular absorber and its geometry. Cavitation and bubble dynamics depend on the pulse format and local environment in retinal/melanosome models [13]; those experiments do not set a viable human iris exposure window. A mechanistic experiment must report wavelength, pulse width, pulse format, beam/spot profile, delivered energy or fluence at the target, repetition, cumulative exposure, and anatomical location, while documenting tissue viability and damage independently of color. The present synthesis provides no Lumineyes-specific tissue-sparing threshold.

Direct experimental iris evidence

In 12 pigmented rabbits, Yildirim and colleagues studied 532-nm Q-switched Nd:YAG exposure at two energy settings and reported reduced anterior iris stromal pigmentation, pigment-containing macrophages, and histological changes including depletion or disappearance of anterior stromal melanocytes in exposed tissue [8]. Melanophage accumulation and retained pigment clumps should not be equated with completed clearance; absence of gross iris-thickness change is not evidence of cell preservation. Under their study conditions, no posterior iris pigment epithelial alteration was identified histologically, but that observation does not establish equivalent effects with other pulses, spots, exposures, or in human eyes. Their short-term rabbit observations test a possibility of compartment-differentiated injury, not selective survival of every anterior stromal cell.

A separate iris-directed rabbit experiment used an SLT-class 532-nm system to induce a steroid-responsive anterior-chamber inflammatory model [31]. These studies together require the intended pigment response to be evaluated against melanocyte integrity, non-melanocyte stromal structures, vasculature, posterior pigment epithelium, corneal endothelium, and functional consequences. Target-associated pigment alteration and anatomical preservation are therefore distinct results that must be measured in the same exposure experiment.

Controlled Pigment Response: Modification, Processing, and Recovery

Pigment liberation is a desired, integral event in SSMM. The clinical question is not whether liberated pigment should be abolished, but how release-generating exposure should be distributed, interrupted and resumed in the context of the eye's response. Staging offers a controllable clinical lever: after an exposure block, the clinician can reassess pigmentary change, inflammation, pressure, recovery and tissue tolerance before inducing additional release. P-CLEAR provides the complementary mechanistic argument that release and biological processing are dynamic rather than necessarily synchronous [14, 25, 44].

The operative chain can be stated as Target → Deliberate pigment modification/release → Ocular processing and physiological response → L-SAFE-supported reassessment → Next exposure decision. LIPS and L-OAT describe the phenotype and optical-architectural starting point; P-CLEAR concerns liberation, residence and handling of material; TRA and LRS describe temporally separable responses. These linked constructs explain why SSMM is not reducible to a wavelength, energy setting, fixed session number, or photographic color endpoint [14, 20–22, 25, 44].

Pigmentary change, intracellular or extracellular pigment handling, and tissue response may proceed at different rates and may diverge between eyes or across stages. Colorimetric endpoints, aqueous particle measurements, optical imaging, and physiological measures therefore answer different questions and require distinct controls.

A directly relevant experimental principle is that pigment burden and outflow function are not linked by a permanent-obstruction rule. Epstein and colleagues infused iris/ciliary-body pigment into living monkey eyes and observed an acute 64% reduction in outflow facility followed by a return to baseline at one week; repeated pigment perfusions did not cause enduring facility abnormalities in that model [41]. This demonstrates biological recovery after a defined particulate challenge, while neither establishing a human SSMM clearance time nor proving that all pigment loads are tolerated. It

supports response-guided reassessment as a meaningful alternative to assuming either inevitable obstruction or effortless clearance.

The defining advantage of the SSMM design is the availability of a response-conditioned control point between exposure stages. A persistent inflammatory response, pressure elevation or concern about corneal or angle status can alter the next decision instead of being overridden by a predetermined total-exposure target. This clinical control does not require pigment release to be absent and does not imply that liberated pigment has been directly counted. It supplies a rational mechanism for limiting avoidable continued exposure while retaining intended pigment modification [14, 25, 44].

Independent challenge experiments illustrate why the state of the recipient tissue matters. After phagocytic exposure of cat trabecular meshwork, the extent of cellular injury and recovery differed substantially among blood, microspheres and zymosan; zymosan-associated cell depletion recovered over approximately 150 days in that animal model [53]. These timings cannot prescribe a retreatment interval for human iris treatment. They do show that particle identity, inflammatory context and recovery status may be physiologically more informative than a fixed cumulative-session schedule, reinforcing the distinct control function of L-SAFE.

Human iris studies show that melanocyte pigmentation may be influenced by fibroblast-dependent signals [15] and that matrix metalloproteinases and their inhibitors are present in iris/ciliary tissues [16]. These are relevant biological properties, but neither paper tests post-laser stromal regeneration or recovery after pigment modification. The present synthesis uses them to identify distinct measurable cell–matrix domains, not to infer an equivalent laser-repair pathway.

Pigment processing should be described as a set of competing fates rather than a linear clearance sequence. Pigment-bearing macrophages may indicate uptake, sequestration, or redistribution; their presence alone does not quantify net clearance from the anterior segment. A future study should characterize particle size/distribution and location over time, distinguish cellular internalization from soluble products, and separately measure inflammation and trabecular outflow [8, 28, 33, 41].

More specific evidence for active processing is now available. AIM/CD5L enhanced particle uptake in human trabecular meshwork cells through an association with CD36; following laser iridotomy in mice, AIM deficiency delayed iris-debris removal and the return of elevated IOP toward baseline [47]. Human trabecular organ cultures, however, have shown that not every encountered particle is engulfed and that free material can persist in intertrabecular spaces and Schlemm's canal [52]. Thus, P-CLEAR should treat competent cellular uptake, residual particulate residence, and downstream outflow response as separable biological variables rather than a guaranteed linear clearance sequence.

Distinction From Classical Pigment Dispersion Syndrome

Classical pigment dispersion syndrome (PDS) and SSMM-related pigment release must not be conflated. Classical PDS is characteristically linked to posterior iris pigment epithelial disruption in the setting of iridozonular contact; the intended SSMM target is anterior stromal melanin, engaged through a staged clinician-directed exposure [17, 44]. Different source compartments and initiating events preclude automatic transfer of PDS pathogenesis or disease incidence to SSMM. They do not

eliminate the shared downstream need to account for pigment reaching the aqueous outflow system, which is why its status is explicitly evaluated [14, 17, 25].

The presence of pigment in the anterior chamber is not, by itself, a diagnosis of classical PDS or proof of glaucomatous obstruction. Nor does anterior origin guarantee harmlessness. Pigment particle properties, exposure rate, residence time, trabecular cellular responses and the state of the eye are mechanistically relevant. Pigment-challenge models show that sufficient particulate exposure can alter trabecular cytoskeletal and phagocytic behavior; these models do not establish a universal threshold for staged SSMM exposure [28, 33, 41, 42].

Serious pressure-related injuries after some cosmetic iris-laser exposures have been documented [18, 27, 37, 38]. These reports matter because they establish that severe events are possible. They do not, however, establish how frequently such events occur within an exposure-defined SSMM population: selected case reports have no treated-population denominator and typically do not establish equivalent targeting, staging or response-guided management. It is therefore methodologically unsound to infer either universal danger or universal safety from them. Risk assessment must distinguish the actual method, the exposure, the anatomical target, the monitored ocular response and the observed follow-up [18, 27, 37, 38, 46]. A short clinical report of iris-directed exposure for sectorial heterochromia [39] is also part of the heterogeneous procedural literature; its size and follow-up do not establish the risk profile of SSMM or of cosmetic iris laser practice generally.

The scientific comparison is between defined treatment architectures and their outcomes, not between a named syndrome and a broad procedural category. SSMM offers a specified biological target, planned pigment liberation, staged exposure and an explicit continuation decision informed by L-SAFE; these are distinctions that can be documented and evaluated. Independent complication reports and the Lumineyes™ practice archive should therefore both be read at their proper evidentiary level, without treating unlike procedures as a single homogeneous intervention [25, 44, 46].



Figure 1. Anatomical target and source of pigment in SSMM and classical PDS.

Legend. Conceptual anatomical comparison

The Lumineyes™ Conceptual Fingerprint

The Lumineyes™ Conceptual Fingerprint is the methodological identity of SSMM: Selective Stromal Melanin Modulation + Controlled Treatment-Related Pigment Response + Response-Guided Staged Treatment. The longitudinal LRS layer examines whether the intended pigmentary effect can be distinguished from concurrent ocular responses across successive stages. Its clinical sequence is Target → Controlled Pigment Release → Observed Response → L-SAFE-Supported Decision, rather than indiscriminate pigment removal followed by an automatic next session [25, 44].

The fingerprint is a positive argument for biological control. Selective optical targeting addresses where energy is intended to act; staged pigment liberation addresses how much new response is initiated before reassessment; ocular surveillance addresses whether further exposure remains acceptable; and L-SAFE formalizes safety-oriented assessment. Staged treatment was previously described in other contexts [9], but those earlier descriptions do not erase the distinctive integration and clinical-control rationale articulated for Lumineyes [25, 36, 44].

The physiological argument has two directions. Pigment loading can impair trabecular function or outflow in experimental models [28, 33, 41, 42], whereas Alvarado et al. documented monocyte-associated augmentation of outflow under SLT-related and macrophage-infusion conditions [19]. Taken together, the literature does not support a universal assumption that pigment-associated stimulation can only obstruct outflow. It supports considering burden-dependent dysfunction and

potentially adaptive cellular signaling as competing processes, without claiming that the latter has already been demonstrated after iris-directed SSMM [43, 45].

SSMM therefore advances a specific methodological thesis: when intentional pigment liberation is staged and the next exposure is contingent on the observed ocular response, the clinician can avoid automatic cumulative loading in an eye that has not recovered sufficiently. This is a rationale for reducing avoidable exposure, not a demonstrated reduction in complication incidence. The author-developed L-SAFE, P-CLEAR, TRA, LRS and SSMM–IOP records specify the interconnected control, kinetic and physiological dimensions of this program [14, 22, 25, 43–45].

Figure 4. L-SAFE Clinical State Architecture

Pre-re-exposure assessment domains and response-guided stage decisions within Lumineyes™



Conceptual diagram: L-SAFE summarizes a clinical decision architecture rather than validated numerical thresholds.

Figure 4. Proposed L-SAFE clinical state architecture. L-SAFE organizes pre-re-exposure assessment across five monitored domains: pressure behavior, inflammatory activity, corneal/endothelial recovery, angle/outflow status, and iris/pupil/visual function. Their integrated state determines whether staged treatment proceeds, is modified, delayed for recovery, or stopped. Conceptual diagram; no validated threshold values are implied.

Evidence-linked conceptual statement. The method makes one operationally falsifiable assertion: for a comparable desired pigmentary endpoint, the amount and timing of release-generating exposure and the ocular response that governs the next stage are clinically consequential variables. The fingerprint [44] supplies the procedure-level control logic; P-CLEAR [14] supplies the kinetic rationale; L-SAFE [25] supplies the assessment logic; and SSMM–IOP [43, 45] supplies a candidate physiological consequence. Independent optical, iris, trabecular and immune-cell studies [5, 8, 19, 28, 33, 41, 42] provide mechanistic anchors. Neither this integration nor those analogies are substituted for direct comparative clinical outcomes.

Phenotype and Interindividual Response Variability

Regional optical accessibility cannot be deduced reliably from a broad visible color category. Spatial heterogeneity and depth-specific pigment distribution are possible sources of between-eye variation and motivate pre-exposure imaging and standardized regional analysis.

The proposed Lumineyes Iris Pigmentation Scale (LIPS) describes apparent anterior stromal pigmentation in five categories [20]. Grades I–IV are ordered by diffuse apparent pigmentation; Grade V is defined by marked spatial heterogeneity and should not be read as a darker grade above IV. LIPS is not yet a validated severity measure, and its interobserver reliability, sensitivity to change, and predictive utility remain empirical questions.

Lumineyes Optical Architectural Typology (L-OAT) is a separate proposed framework for optical and architectural phenotype [21]. Neither naming a phenotype nor assigning a category demonstrates that it predicts response. Independent grading, standardized acquisition, and out-of-sample performance testing are required.

Quantitative image analysis can resolve differences obscured by broad categorical eye-color labels, as demonstrated by CIELAB-based population iris measurements [34]. This supports objective phenotyping, not the untested conclusion that a particular LIPS or L-OAT label predicts laser response. A treatment-response test must compare regional standardized color and optical-architecture variables against gross-color and exposure-only models in independent, patient-level validation data.

Longitudinal Response Selectivity (LRS)

Definition and position

Longitudinal Response Selectivity (LRS), proposed within the SSMM framework in 2026, is defined below as an evaluation concept rather than an additional optical targeting mechanism.

Longitudinal Response Selectivity (LRS) is a proposed *measurement and interpretation construct*: under specified visit windows and exposure conditions, it asks whether intended pigmentary change and prespecified tissue-response domains can be empirically distinguished over time. It is not a fourth biophysical selectivity mechanism, a validated score, or proof of clinically favorable recovery.

Operationally, LRS couples repeated observation with separate definitions for pigmentary and non-pigmentary responses (Figure 2). Distinguishable trajectories would not prove selective targeting or preserved anatomy; those questions require independent endpoints.



Figure 2. Positioning of Longitudinal Response Selectivity (LRS) within the SSMM framework.

Legend. The three SSMM selectivity dimensions—biophysical, anatomical, and functional—are examined through repeated assessment. LRS denotes the extent to which intended stromal pigment modification can be distinguished from accompanying tissue responses across observation periods and treatment stages. These observations may inform response-guided staged treatment. LRS is a longitudinal evaluation concept, not a fourth optical selectivity mechanism or a validated numerical score.

Temporal interpretation

The exposure is brief relative to the possible evolution of pigmentary, sensory, inflammatory, anatomical, and functional responses. Measurements restricted to one postoperative time point may therefore conflate domains that differ in onset or persistence (Figure 3). The plotted curves are strictly illustrative; no SSMM-specific kinetic constants are inferred.

Temporal Response Architecture (TRA) is a related proposed naming system for response domains [22]. LRS poses the narrower empirical question of whether these trajectories can be reliably distinguished with repeated measurement, without assuming that any one temporal pattern is favorable.



Figure 3. Conceptual temporal trajectories of intended pigmentary change and accompanying tissue responses.

Legend. Panel A depicts hypothetical, non-clinical normalized trajectories for the intended pigmentary response P(t) and three accompanying response domains: sensory $R_1(t)$, inflammatory $R_2(t)$, and anatomical $R_3(t)$. Panel B distinguishes pigment modification, possible pigment processing, and subsequent tissue response. The curves are an explanatory schematic, not patient measurements, incidence estimates, or a predicted post-treatment course; axes and temporal placement must not be interpreted quantitatively.

Operational assessment

Let P(t) denote a pigmentary endpoint selected before data analysis and $R_1(t)...R_n(t)$ denote separately defined sensory, inflammatory, anatomical, or physiological endpoints. LRS distinguishability requires an estimable temporal or stage-specific contrast beyond known measurement error in a specified exposure, population, endpoint pair, and follow-up window. A shared trajectory fitted as a comparator model should be considered, rather than assuming different scales imply different biological kinetics. The inference is neither tissue preservation nor causal independence. A precise null may challenge a prespecified LRS contrast; an imprecise null remains inconclusive.

An LRS study requires baseline observations, standardized imaging and lighting, pupil size and regional registration, reliable independent grading, repeatability estimates, declared visit windows, treatment/session timestamps, cumulative exposure and medications, and prospective adverse-event ascertainment. Longitudinal models should account for measurements nested within eyes and eyes within patients, differential follow-up, time-dependent confounding, and missingness. Prespecified contrasts should be accompanied by intervals and measurement-error sensitivity analyses [26, 34].

LRS must be separated into three levels of inference. Description: do distinct, reproducible pigmentary and tissue trajectories exist for the chosen domains? Prediction: does prior-stage, time-resolved information improve held-out calibration and prediction beyond a locked baseline/exposure model [35]? Decision benefit: would using the additional information improve prospectively evaluated management decisions, compared with an explicit alternative rule [36]? Success at one level

does not establish the next. No validated LRS cutoff, favorable trajectory, or treatment algorithm is currently available.

Prespecified interpretation of longitudinal findings

For each domain, investigators should report instrument repeatability, smallest detectable change or an empirically justified decision threshold, relevant follow-up horizon, and uncertainty around between-domain contrasts. Image colorimetric change, anterior chamber flare, particles, corneal endothelial metrics, IOP, and visual function have noninterchangeable measurement scales. Small-particle OCT signatures and flare readings do not identify pigment mass, complete clearance, or a benign cellular response [23, 24].

Table 2. Candidate longitudinal measurements for evaluating LRS

Response domain	Candidate observation/measurement	What it establishes
Intended pigmentary response P(t)	Standardized iris photographs; registered regional color/phenotype analysis	Visible optical change, not directly liberated melanin mass
Sensory response	Repeated standardized photophobia and light-associated discomfort assessments	Patient-reported course, not a direct anatomical measure
Inflammatory response	Slit-lamp cell/flare assessment; optional laser flare photometry; exploratory SS-AS-OCT particle metrics	Flare quantifies aqueous protein scattering; OCT particle characteristics are not definitive cell/pigment identification [23, 24]
Anatomical response	Registered anterior-segment OCT; serial specular microscopy (endothelial cell density and morphology)	Structural and endothelial outcomes distinct from visible corneal clarity
Functional response	Relevant ocular clinical and physiological measures across defined visits	Endpoint-specific functional trajectory

Clinical Foundations and Longitudinal Lumineyes™ Observations

Program context

The Lumineyes™ Clinical Data archive is a substantive record of the author's clinical experience with the developing methodology, not merely a historical explanation for the framework. It summarizes approximately 1,500 patients and more than 3,000 treated eyes over 2017–2026. The archive reports a 97.4% clinic-assessed pigment-response result, approximately 15 patients with transient early postoperative IOP elevations, transient corneal edema/Descemet-fold findings in approximately 3% of treated eyes, and no documented cases of progressive post-treatment IOP elevation or treatment-associated permanent visual loss in the records summarized to date [46]. These observations were made within a physician-led practice and are reported explicitly as the author's longitudinal clinical observations.

The archive is clinically relevant precisely because it can be organized at the patient, eye, session, examination and treatment-course levels. Its reported age span is 18–71 years at initial treatment, and selected recorded follow-up extends to 96 months [46]. These are program-level observations across an evolving nine-year practice—not nine-year complete follow-up for every treated eye. Eye-level and patient-level event counts should retain their own denominators, while the legacy 97.4% clinic-

assessed pigment-response estimate should be accompanied by the exact event definition and analysis unit when patient-level extraction is finalized.

This accumulated clinical experience has direct scientific relevance: it is the setting in which repeated staged exposures, visible pigment liberation, differential recovery and pressure surveillance were observed and used to refine decisions. The value of the archive is its longitudinal method-specific clinical context and its capacity to support patient-, eye-, session- and visit-level analysis. Its published summary provides useful descriptive evidence of what was observed; an exact incidence analysis will require reconciliation of eligible eyes, follow-up completeness and outcome definitions [46].

A subsequent formal clinical analysis should specify the underlying cohort, treatment-era strata, follow-up distribution, adverse-event definitions, paired measurements and missing-data handling. These are conventional requirements for calculating comparative rates and mechanistic associations; they do not negate the existence or the clinical provenance of the physician's recorded observations.

Response-Guided Clinical Refinement

The method matured through clinical selection, exposure staging, postoperative management and interval-based reassessment. That evolving clinical practice is a reason to analyze treatment-era and exposure-history differences rather than assume the program was technically static. A rigorous analysis can exploit those longitudinal distinctions by recording stage, session number, iris phenotype, recovery interval, medications and the corresponding outcomes [46].

Sensory trajectories

Photophobia and light-associated discomfort are plausible observation domains arising from the clinical program; their occurrence, severity, duration, and relation to treatment stage have not been quantified in a protocolized dataset for this synthesis. A study designed to address them should capture light-exposure context, standardized patient-reported ratings, and repeated symptom assessment rather than substitute clinical recollection for incidence estimates.

Corneal and endothelial trajectories

Corneal edema and Descemet membrane folds are meaningful anatomical findings but do not directly quantify endothelial cell loss. In separate Nd:YAG iridotomy literature, endothelial density changes have been investigated with serial specular microscopy [29]; the exposure geometry is not equivalent to laser iris depigmentation. SSMM-specific follow-up should therefore include standardized corneal examinations and, where feasible, serial endothelial cell density and morphology, rather than inferring normal endothelial function from a clear cornea.

Inflammatory trajectories

Anterior-chamber cells and flare, iridocyclitis, and fibrin are distinct endpoints and should not be combined as a nonspecific "inflammation" outcome. A clinical study should report cell/flare grades using standardized uveitis nomenclature, timing relative to exposure, and topical/systemic medication use or adherence as covariates [40]. In animal iris-laser experiments, steroid exposure can alter the ensuing inflammatory and pressure course [31]. Laser flare photometry gives an objective aqueous-scattering measure but does not quantify released melanin or stromal repair [23].

Pressure Observations and Long-Term Ocular Function

The Lumineyes™ archive records approximately 15 transient early IOP-elevation cases among roughly 1,500 patients and no documented progressive post-treatment IOP elevation in its available longitudinal summary [46]. These are clinically consequential observations for understanding the staged approach, although exact incidence and time-specific pressure effects must be calculated from linked examination records. Physiologically, pigment challenge can transiently reduce outflow facility [41], trabecular cytoskeletal changes can accompany pigment loading [33], and elevated pressure may precede measured phagocytic decline in experimental work [42]. Distinct monocyte-associated responses can increase outflow facility after SLT or macrophage exposure [19]. SSMM–IOP [43, 45] integrates these observations into a competing-mechanism explanation for early and later pressure behavior; it does not require that all eyes follow a single pressure trajectory.

Competing outflow hypotheses and discriminatory experiments

The two porcine pigmentary glaucoma experiments cited here answer different questions: the ex vivo model documents impaired outflow with cytoskeletal and phagocytic changes [33], whereas the separate time-sequence investigation addresses whether pressure elevation precedes a reduction in phagocytic activity [42]. Neither model reproduces iris-directed laser exposure. Pigment generated for these experimental challenges should not be assumed equivalent in composition or dose to particles liberated from a treated living iris.

Recent immune-cell studies support a more specific physiological distinction. In mice, selective depletion of long-lived resident macrophages in resistance-generating outflow tissues increased IOP and outflow resistance alongside altered extracellular-matrix turnover [48]. These tissue-resident macrophages are functionally distinct from newly recruited monocyte-derived cells. Therefore, the monocyte recruitment observed after SLT [19] should not be treated as direct evidence that pigment-loaded cells released during SSMM activate the same homeostatic macrophage program. Instead, the two populations define complementary, experimentally separable routes by which outflow physiology may respond to perturbation.

A mechanistic study should prospectively specify alternative mechanisms rather than interpret a single pressure change as evidence for adaptation. In suitable perfused anterior-segment systems, candidate arms could include sham, a physically characterized pigment challenge, laser-conditioned medium without pigment particles, combined pigment and conditioned medium, and pathway perturbations with matched controls. Particle-origin and size distributions, medium conditioning, recipient anatomy, and delivered exposures must be defined before experimental interpretation. Outcomes should include time-resolved facility, particulate localization, trabecular viability/contractility, phagocytic function and, where feasible, macrophage phenotype and cytokine/MMP signaling [19, 33, 41, 42]. This is a proposed discriminatory design, not an established SSMM protocol; neither impaired nor improved outflow is assumed.

Outflow regulation also has soluble and mechanically responsive components. Conditioned medium from laser-activated trabecular endothelial cells increased Schlemm-canal endothelial permeability in vitro, supporting a paracrine route that need not depend on physical particle obstruction [55]. FYN-dependent phosphorylation of VE-cadherin has been implicated in Schlemm-canal junctional permeability and IOP regulation [54]. Laser trabeculoplasty can elicit IL-1β/TNF-α-dependent matrix-

metalloproteinase signaling [56], while pigment-phagocytosis experiments show that expression of matrix-remodeling genes does not by itself establish durable functional collagenolysis [51]. These pathways explain why a sustained outflow hypothesis requires separate functional measurements rather than pressure readings alone.

Table 3. Competing pigment-associated outflow hypotheses and discriminatory readouts

Candidate pathway	Independent evidence / limitation	Discriminating outcome
Particulate obstruction	Primate pigment infusion acutely reduced facility but recovered [41]; not iris-laser exposure.	Particle count/size/localization and real-time outflow facility.
TM cell dysfunction	Porcine ex vivo pigment model implicated cytoskeletal/RhoA changes [33].	Contractility, viability, actin architecture and facility.
Phagocytosis changes	In a separate porcine perfusion study, IOP elevation preceded measurable phagocytic decline [42]; not an iris-laser model.	Temporally paired facility/IOP, particle load and cell-uptake assays.
Adaptive macrophage response	Monocyte-associated effects documented after SLT, not SSMM [19].	Cell origin, cytokine phenotype, localization and facility.
Inflammation / medication	Iris-directed rabbit 532-nm exposure elicited inflammation; drugs can modify response [31].	SUN cell/flare, drug timing, fixed-time IOP, facility where feasible.

Scientific Contribution and Integrated Lumineyes™ Research Program

SSMM contributes an explicit, clinical procedure-level control architecture for intentional anterior stromal pigment release. Its components are linked causally and operationally: select an optically meaningful stromal target; induce a bounded staged pigment response; observe the receiving anterior segment; and use that response to determine whether, when and how the next exposure occurs. The contribution is not simply the naming of known laser or monitoring principles, but their integration into a defined response-guided clinical methodology developed through direct practice [12, 14, 25, 44, 46].

The author-developed program is not a disconnected collection of names. SSMM provides the governing target-and-control architecture; LIPS and L-OAT provide baseline pigmentary and optical phenotype; P-CLEAR explains the proposed release–processing balance; TRA and LRS organize time-dependent response; L-SAFE supports the assessment that determines whether another exposure is appropriate; and SSMM–IOP examines downstream pressure/outflow possibilities, including competing cellular and matrix pathways [14, 20–22, 25, 43–45]. These publications establish the internal conceptual coherence and provenance of the program, while independent studies provide its direct experimental and physiological foundations.

The appropriate scientific demand is to evaluate that defined architecture using reproducible exposure descriptors and clinically meaningful endpoints. The existence of earlier research in selective optical targeting, iris color change and sequential decision theory does not remove the distinct question of what occurs when selective stromal pigment modulation, controlled release and response-guided staging are practiced as a linked system [5, 8, 9, 25, 36, 44].

SSMM does not claim invention of melanin absorption physics or the general concept of clinical reassessment. It asserts something narrower and clinically concrete: intended pigment liberation can be organized as a continuously reassessed exposure–response process instead of a fixed-dose pigment-removal event. This structure provides a defensible rationale for pursuing the desired optical

change while preserving the clinician's ability to respond to inflammation, pressure, corneal status, angle physiology and tissue recovery [14, 25, 44, 46].

Table 4. Scientific contribution matrix

Domain	Established foundation	Proposed SSMM contribution
Optical targeting	Preferential chromophore interaction	Defined target hypothesis; experimental specificity remains unverified
Tissue response	Laser-induced physical and biological effects	Separate pigmentary outcomes from surrounding structural findings
Stromal biology	Melanocyte–fibroblast interactions; matrix regulatory proteins	Separate measurement of pigment, cell and matrix trajectories
Longitudinal response	Different domains evolve on different timescales	LRS as a test of distinguishable within-eye trajectories
Clinical management	Staging and clinical reassessment	Test of incremental value from prior-stage observations

Testable Propositions

Proposition 1 — Preferential target interaction. Under a documented wavelength, pulse/spot/exposure distribution, anterior stromal pigment-bearing regions will show a reproducibly greater initial pigment-associated physical response than anatomically comparable adjacent lower-pigment regions, when assessed with calibrated optical measurements and masked viability/histological damage mapping. A finding of equivalent response, or clinically material non-target injury despite pigment change, would challenge selectivity at that exposure; it would not refute all possible exposures.

Proposition 2 — Pigment–anatomy dissociation. In anatomically registered regions, measured pigmentary change and direct stromal cell/matrix/vascular injury will not be interchangeable endpoints. The study must jointly quantify color, melanocyte integrity, structural matrix status, posterior epithelium, and adjacent tissue changes under the same exposures. If apparent pigment change is inseparable from unacceptable or proportional cellular damage within the precision of the assays, a claim of tissue preservation is not supported; non-detection is not proof of equivalence.

Proposition 3 — Phenotype dependence. Prespecified regional pigment density, heterogeneity, and optical-architectural features will predict subsequent pigmentary response beyond gross iris-color category and documented exposure alone. Training, tuning, and evaluation must be separated at the patient level, using masked phenotype assessment and independent validation; absence of calibrated incremental performance challenges the proposed phenotype utility [26, 34].

Proposition 4 — Longitudinal response differentiation. At specified follow-up windows, at least one preselected pigment–nonpigment response pair will show an estimable difference in timing or magnitude larger than its independently determined measurement-error limits. The model must include within-eye correlation, bilateral clustering, missingness, treatment interval, and medication effects. An imprecise null result is inconclusive; a sufficiently precise nondifference challenges LRS distinction for that pair and setting.

Proposition 5 — Incremental stage information. Earlier-stage responses will improve held-out prediction of a prespecified later outcome over a locked baseline-plus-cumulative-exposure model at a

declared horizon, assessed using calibration and proper scoring or discrimination metrics [35]. The separate claim that history-informed rules improve treatment decisions requires prospective comparison with a stated alternative strategy; prediction gains alone cannot establish clinical benefit [36].

Proposition 6 — Cumulative and long-term response. A specific, separately testable version would compare a documented eye-level cumulative exposure metric with an a priori primary outcome, such as baseline-adjusted, time-standardized IOP at a declared 12-month visit, while accounting for baseline pressure, age, medication, treatment era, prior exposures, and repeated observations. The exposure definition, time window, minimum practically relevant association, statistical precision target, and missing-data handling must be specified before analysis; a sufficiently narrow interval excluding that minimum association would challenge the specified exposure–response hypothesis. Adverse effects and null results remain reportable. This illustrative test neither predicts pressure reduction nor generalizes to other anatomical or functional outcomes.

Proposition 7 — Mechanistic discrimination. Under controlled, suitably contrasted conditions, combining direct outflow facility with characterized pigment particles, cellular/conditioned-medium signals, and structural readouts will distinguish at least some competing physical-obstruction, trabecular-dysfunction, and macrophage-response models [19, 33, 41]. IOP alone, a single inflammatory marker, or pigment appearance without particle measurements cannot identify the pathway. Indistinguishable model predictions despite adequately powered discriminating assays would limit mechanistic utility.

Table 5 specifies candidate tests and results that would weaken each proposition. The comparator, primary endpoint, sampling unit, measurement precision, effect criterion, and exposure window should be registered before analysis. Successful predictions in one source or setting do not imply treatment efficacy, and apparent null findings must be interpreted relative to assay sensitivity and uncertainty.

Table 5. Operational tests, comparators, and disconfirming results for the seven SSMM propositions

SSMM proposition	Primary test / comparator	Result challenging the proposition
Preferential targeting	Paired mapped iris regions: calibrated exposure + optical response, cell viability, masked injury map	No reproducible target preference or material non-target injury
Pigment–anatomy	Registered pigment, melanocyte, matrix, vascular and epithelial endpoints under same exposure	Tissue preservation unsupported when injury remains inseparable from change
Phenotype dependence	Patient-held-out prediction from regional baseline phenotype vs gross color + exposure	No incremental, well-calibrated predictive performance
LRS differentiation	Paired domain-specific time courses versus premeasured error and standardized visits	Sufficiently precise null temporal contrast for specified outcome pair
Stage information	Locked prediction models with and without prior responses; decision strategy tested separately	No incremental prediction; no separately demonstrated decision benefit
Cumulative exposure–response	Prespecified exposure metric versus baseline-adjusted 12-month timed IOP, with medication and follow-up controls (illustrative primary test)	A precise interval excluding the prespecified minimum relevant exposure–response association for this endpoint

SSMM proposition	Primary test / comparator	Result challenging the proposition
Outflow mechanisms	Pigment, conditioned-media, combined and control arms; facility + particle/cell readouts	Non-discrimination among specified mechanisms despite adequate measurement

Research Priorities

Quantitative phenotyping. Use standardized iris photography and registered region-based colorimetry with fixed acquisition conditions, masked graders, repeatability testing, and prespecified target regions [26, 34]. Compare regional continuous predictors with gross-color classes, and require patient-level, out-of-sample evaluation before attributing predictive validity to LIPS or L-OAT.

Experimental laser–tissue studies. A controlled iris-donor or appropriate animal exposure matrix should document delivered beam geometry, wavelength, pulse temporal form, spot profile, target depth, exposure distribution and local pigmentation. Assess initial target response alongside melanocyte viability, stromal matrix, vascular and endothelial injury, macrophage/pigment retention, and posterior epithelial status; historical rabbit observations show that visible depigmentation can coexist with melanocyte depletion [8, 31]. No rabbit exposure threshold should be reused as a presumed human safety threshold.

Longitudinal clinical analysis. Prespecify patient-, eye-, session-, region-, and event-level denominators; account for bilateral correlation and visits nested within eyes, treatment era, cumulative exposure, and time-dependent medication. Document follow-up distribution, missingness, standardized adverse events, time-matched IOP, gonioscopy, corneal/endothelial measurements, and visual-function endpoints. Audit actual source records under a separate research-ethics and data-governance determination rather than converting clinical recollection into rate estimates [40].

Corneal endothelial assessment. Serial endothelial cell density, polymegathism, pleomorphism, and corneal thickness are candidate measurements that can reveal changes not evident from clinical clarity. Baseline comparability, age, cumulative exposure, and measurement repeatability are essential [29].

Adaptive assessment. First test whether the histories of objectively defined pigmentary and tissue responses improve out-of-sample outcome prediction over locked baseline/exposure features, with calibration and net predictive value reported [35]. Only then evaluate a prospectively specified history-informed management rule versus an explicit alternative strategy, using an appropriate sequential or randomized design [36]. Prediction and causal decision benefit must not be treated as synonymous.

Aqueous outflow as an SSMM physiological branch. Pigment challenge can transiently obstruct outflow in monkeys [41]; porcine models show cytoskeletal and phagocytic dysfunction [33] and an IOP rise preceding measured phagocytosis decline in a separate study [42]. Conversely, monocyte recruitment and macrophage-associated increases in outflow facility have been demonstrated in non-SSMM experiments [19]. The SSMM–IOP synthesis brings these observations together with candidate fast Schlemm-canal junctional/contractile responses and slower extracellular-matrix feedback, proposing that a pigment-associated perturbation could be followed by higher, unchanged, or lower

IOP depending on burden and ocular response [43, 45]. The lower-pressure branch is a mechanistic possibility, not a measured average effect or a demonstrated sustained response to Lumineyes. Direct outflow-facility testing, comparable tonometry, gonioscopy and medication review would differentiate these pathways.

Figure 5. SSMM–IOP Competing Mechanistic Branches

Conceptual pathways linking staged controlled pigment release to higher, unchanged, or lower IOP



Determinants include particulate burden, release kinetics, recovery interval, host cellular response, and pre-existing outflow state.

Conceptual diagram only: the lower-IOP branch is a biological possibility, not a claimed average clinical effect.

Figure 5. SSMM–IOP competing mechanistic branches. After staged controlled pigment release, outflow-state change may follow burden-dominant, balanced/neutral, or adaptive-response pathways, with higher, unchanged, or lower IOP as possible outcomes. The lower-IOP branch is a mechanistic possibility, not a claimed average clinical effect.

Clinical interpretation of safety evidence. Serious complication reports [18, 27, 37, 38] provide necessary evidence of possible harm from particular iris-directed exposures; they do not supply a method-specific incidence estimate for SSMM. Conversely, the author's large longitudinal archive reports a favorable pattern of documented clinical observations but is not a randomized comparison or a denominator-verified postmarketing surveillance dataset [46]. Both forms of evidence should be retained, with the intended method and its staging/assessment architecture specified. Neither selective publication of complications nor selected clinical observations can replace a defined cohort analysis.

Discussion

The principal position of this review is that SSMM provides a biologically reasoned control architecture for Lumineyes™, not a generic appeal to caution. The method intentionally generates anterior stromal pigment modification and release, yet its logic is to avoid automatic continuation without evaluating the eye's actual response. The clinical control point between stages is valuable precisely because optical pigment response, inflammatory status, pressure and tissue recovery need

not evolve together. L-SAFE converts that concept into a structured re-exposure assessment, while P-CLEAR provides a mechanistic account of the material that enters ocular processing pathways [14, 25, 44].

Independent science supports key elements of this argument. Melanin can be targeted preferentially by optical exposure [5], and a controlled rabbit iris study demonstrated anterior pigment alteration with no histological change of the posterior pigment epithelial layer under its tested conditions, despite important changes in anterior melanocytes [8]. Experimental pigment loading can alter aqueous outflow, trabecular contractility and phagocytic function [28, 33, 41, 42], whereas other experimental conditions show monocyte-associated facilitation of outflow [19]. These findings do not establish identical laser outcomes across systems. They do establish that the target, exposure distribution, the fate of liberated pigment and the receiving tissue's response are scientifically material variables—the variables SSMM places under active clinical consideration [14, 25, 43].

Together, the newly identified experiments make the SSMM rationale more specific. The receiving outflow pathway can process a finite particulate challenge and recover [41, 47, 52, 53]; its resident immune cells contribute to baseline resistance and matrix homeostasis [48]; and endothelial junctions, cytokine-mediated signaling and distal-vessel responses supply independently demonstrated routes for pressure regulation [49, 54–56]. SSMM integrates these known physiological possibilities into a deliberate clinical sequence in which intentional stromal pigment release is separated by response-guided re-exposure decisions. This is a defensible mechanistic integration, not a claim that one of these routes has already been causally isolated in treated Lumineyes patients.

Mechanistic parallels and evidentiary interpretation. The relevant scientific bridge is convergence of biological mechanisms, not equivalence of interventions. Studies of selective laser trabeculoplasty, experimental pigment challenge, melanosome photophysics, and aqueous-outflow regulation were performed in distinct anatomical targets, exposure conditions, or species; they are not presented here as direct proof of SSMM-specific safety, clinical outcomes, or sustained pressure reduction. Rather, they independently demonstrate processes that correspond to components of the proposed Lumineyes™ architecture: preferential melanin–energy interaction, particulate uptake and recovery, immune-cell signaling, and active regulation of outflow resistance [5, 8, 19, 28, 33, 41, 42, 47–56]. This mechanistic convergence strengthens the biological rationale for staged, response-guided controlled pigment release and offers plausible pathways through which the author-reported clinical observations could arise [43, 46]. The clinical observations and the independent experimental mechanisms remain complementary but distinct lines of evidence; a specific causal link is not claimed where it has not been measured.

The Lumineyes™ archive adds an important, separate level of evidence: approximately nine years of direct, method-specific, physician-recorded clinical observations across a large treated population, including documented pigment response, transient events and longitudinal pressure assessment [46]. Such experience is not interchangeable with a controlled trial, but it should not be dismissed as scientifically irrelevant simply because the analysis has not yet been independently adjudicated. Case reports of harm likewise require attention without being used to infer an SSMM-specific event rate. The most coherent interpretation integrates mechanistic plausibility, the author's clinical experience

and explicitly identified sources of uncertainty, rather than accepting or rejecting the method on the basis of publication category alone.

The SSMM–IOP branch extends the clinical argument without redefining SSMM as a pressure-lowering procedure. Controlled pigment release may perturb the outflow environment; whether pressure rises, stays stable or falls will depend on material load, tissue response, aqueous handling and the time course of any adaptive change [19, 33, 41–43]. In the author's clinical archive, no chronic or progressive post-treatment IOP elevation was documented in the reported observations [46]. The possibility of longer-term lower IOP is therefore a legitimate mechanistic question arising from the combination of clinical observations and independent outflow biology, while proof of a sustained causal facility change requires its own linked measurements [43].

An additional experimental separation is essential: in mice, intracameral puncture without material injection reduced IOP and was associated with distal episcleral-vessel dilation and macrophage recruitment, while conventional outflow-facility measurements at day one were not significantly changed [49]. This establishes that anterior-chamber perturbation can influence pressure through pathways outside a simple trabecular particle-clearance model; it does not establish an analogous response after non-incisional SSMM. Accordingly, plausible lower-IOP observations should be evaluated against changes in trabecular facility, distal resistance, aqueous production, episcleral venous pressure, tonometric variability and concurrent medications.

Conclusion

SSMM is the scientific foundation of Lumineyes™ as a response-guided controlled pigment-release methodology. Its purpose is affirmative and clinically specific: preferentially modulate anterior stromal melanin; deliberately generate a pigmentary response; organize further exposure in stages; assess the ocular state through L-SAFE; and preserve the option to proceed, modify, delay or stop according to observed physiology. This is a defined clinical and biophysical strategy, not a synonym for the heterogeneous category of laser iris depigmentation [12, 14, 25, 44].

The scientific rationale rests on convergent evidence: targeted anterior iris pigment alteration can be demonstrated experimentally [8]; pigment can produce distinct cellular and outflow responses, including both resistance-associated and adaptive pathways under different experimental conditions [19, 28, 33, 41, 42]; and the nine-year Lumineyes™ archive provides method-specific longitudinal clinical observations [46]. L-SAFE, P-CLEAR, TRA, LRS, LIPS, L-OAT and SSMM–IOP connect these elements into a coherent, response-guided clinical framework [14, 20–22, 25, 43–45]. These independent findings are cited for mechanistic correspondence, not as intervention-specific proof; the Lumineyes™ observations remain a separate clinical evidence stream. The resulting claim is not that SSMM has already proved universal safety or reliable pressure lowering, but that staged controlled pigment release and real ocular-state feedback constitute a biologically justified and clinically meaningful way to pursue stromal pigment modification while targeting preservation of anterior-segment function.

Limitations and Future Research

This narrative synthesis and the cited physician-maintained clinical archive do not provide a contemporaneous controlled comparison of SSMM against other exposure architectures, systematic verification of every outcome denominator, complete standardized long-term follow-up, or direct human outflow-facility measurements. Further work should examine linked patient-eye-session records, graded pigmentary and inflammatory endpoints, specular-microscopy and angle measurements, time-standardized IOP trajectories, and independent replication of the release–processing–outflow mechanisms. These studies would quantify the degree of tissue preservation, clarify the pressure-related possibilities and determine comparative safety and effectiveness; they are not prerequisites for articulating the methodology and its scientific rationale. Direct SSMM-specific comparisons, exposure-linked tissue assessment, and mechanistic separation of trabecular, distal-outflow and inflow contributions will be needed to determine the magnitude and persistence of any physiological benefit. The animal and ex vivo recovery periods cited here must not be interpreted as validated human inter-stage treatment intervals.

Declarations

Ethics approval: This narrative synthesis reports no newly enrolled research participants and no new patient-level dataset was analyzed. Any future clinical cohort analysis requires its own applicable ethics and data-governance determination.

Data availability: No new individual-level clinical dataset was generated or analyzed for this article. The cited literature and conceptual research records are identified in the reference list.

Competing interests: The author is the developer of the Lumineyes™ method and the founder of the MyLumineyes™ clinical brand.

References

[1] Imesch PD, Wallow IHL, Albert DM. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 1997;41(Suppl 2):S117–S123. https://doi.org/10.1016/S0039-6257(97)80018-5

[2] Wilkerson CL, Syed NA, Fisher MR, Robinson NL, Wallow IHL, Albert DM. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol. 1996;114(4):437–442. https://doi.org/10.1001/archopht.1996.01100130433014

[3] Borrás T. The cellular and molecular biology of the iris, an overlooked tissue. J Glaucoma. 2014;23(8 Suppl 1):S39–S42. https://doi.org/10.1097/IJG.0000000000000104

[4] Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem Photobiol. 2008;84(3):639–644. https://doi.org/10.1111/j.1751-1097.2008.00316.x

[5] Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220(4596):524–527. https://doi.org/10.1126/science.6836297

[6] Jacques SL. Optical properties of biological tissues: a review. Phys Med Biol. 2013;58(11):R37–R61. https://doi.org/10.1088/0031-9155/58/11/R37

[7] Jacques SL. Laser-tissue interactions: photochemical, photothermal, and photomechanical. Surg Clin North Am. 1992;72(3):531–558. https://doi.org/10.1016/S0039-6109(16)45731-2

[8] Yildirim Y, Duzgun E, Kar T, et al. Evaluation of color-changing effect and complications after Nd:YAG laser application on iris surface. Med Sci Monit. 2016;22:107–114. https://doi.org/10.12659/MSM.895086

[9] Grimaldos Ruiz P. Photoablative cosmetic iridoplasty: effective, safe, and predictable—eye color change in 1176 eyes. Int Ophthalmol. 2021;41:1381–1393. https://doi.org/10.1007/s10792-021-01693-5

[10] D'Oria F, Abu-Mustafa SK, Alio JL. Cosmetic change of the apparent color of the eye: a review on surgical alternatives, outcomes and complications. Ophthalmol Ther. 2022;11:465–477. https://doi.org/10.1007/s40123-022-00458-2

[11] D'Oria F, Alio JL. Surgical techniques for cosmetic eye color change: a narrative review. Ophthalmol Ther. 2025;14:1685–1694. https://doi.org/10.1007/s40123-025-01177-0

[12] Mete M. Selective Stromal Melanin Modulation (SSMM) [preprint]. Zenodo. 2026. https://doi.org/10.5281/zenodo.23424601

[13] Deladurantaye P, Méthot S, Mermut O, Galarneau P, Rochette PJ. Potential of sub-microsecond laser pulse shaping for controlling microcavitation in selective retinal therapies. Biomed Opt Express. 2020;11(1):109–132. https://doi.org/10.1364/BOE.11.000109

[14] Mete M. Pigment Release-Clearance Balance in Selective Stromal Melanin Modulation: A Mechanistic Review and Proposed P-CLEAR Framework [preprint]. Zenodo. 2026. https://doi.org/10.5281/zenodo.23221292

[15] Smith-Thomas L, Moustafa M, Spada CS, et al. Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res. 2004;78(5):973–985. https://doi.org/10.1016/j.exer.2003.12.003

[16] Lan J, Kumar RK, Di Girolamo N, McCluskey P, Wakefield D. Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body. Br J Ophthalmol. 2003;87(2):208–211. https://doi.org/10.1136/bjo.87.2.208

[17] Zeppieri M. Pigment dispersion syndrome: a brief overview. J Clin Transl Res. 2022;8(5):344–350. https://doi.org/10.18053/jctres.08.202205.004

[18] Liu J, Korban S, Moster MR, Rhéaume M-A, Wang Q. Bilateral severe iatrogenic pigmentary glaucoma following laser treatment for cosmetic iris color change. Am J Ophthalmol Case Rep. 2023;32:101927. https://doi.org/10.1016/j.ajoc.2023.101927

[19] Alvarado JA, Katz LJ, Trivedi S, Shifera AS. Monocyte modulation of aqueous outflow and recruitment to the trabecular meshwork following selective laser trabeculoplasty. Arch Ophthalmol. 2010;128(6):731–737. https://doi.org/10.1001/archophthalmol.2010.85

[20] Mete M. The Lumineyes Iris Pigmentation Scale (LIPS): A Proposed Clinical Framework for Grading Anterior Stromal Iris Pigmentation. Zenodo research record. 2026. https://doi.org/10.5281/zenodo.23108463

[21] Mete M. Lumineyes Optical Architectural Typology (L-OAT): A Multimodal Hypothesis for Quantitative Iris Phenotyping. Zenodo preprint. 2026. https://doi.org/10.5281/zenodo.23066772

[22] Mete M. Temporal Response Architecture After Laser-Based Iris Pigment Modification: A Mechanistic Synthesis of Anterior-Segment Response Domains. Zenodo preprint. 2026. https://doi.org/10.5281/zenodo.23128049

[23] Tugal-Tutkun I, Herbort CP. Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol. 2010;30(5):453–464. https://doi.org/10.1007/s10792-009-9310-2

[24] Bellchambers A, Shu R, Chu CJ, Petrushkin H, Solebo AL. Differentiation of anterior chamber pigment and inflammatory cells using swept-source optical coherence tomography: a cross-sectional study. Eye (Lond). 2025;39:1744–1750. https://doi.org/10.1038/s41433-025-03697-2

[25] Mete M. Lumineyes Anterior-Segment Safety Staging (L-SAFE): A Proposed Framework for Pre-Exposure Assessment in Laser Iris Pigment Reduction. Zenodo research record. 2026. https://doi.org/10.5281/zenodo.23046455

[26] Takamoto T, Schwartz B, Cantor LB, Hoop JS, Steffens T. Measurement of iris color using computerized image analysis. Curr Eye Res. 2001;22(6):412–419. https://doi.org/10.1076/ceyr.22.6.412.5490

[27] Ong AY, Ching-A-Sue G, Krilis M, Guirao-Navarro MC, Hornby S, Jutley G. Refractory iatrogenic pigmentary glaucoma secondary to cosmetic laser treatment: a case report. Eur J Ophthalmol. 2023;33(2):NP1–NP4. https://doi.org/10.1177/11206721211050338

[28] Wang C, Dang Y, Loewen RT, Waxman S, Shah P, Xia X, et al. Impact of pigment dispersion on trabecular meshwork cells. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1217–1230. https://doi.org/10.1007/s00417-019-04300-7

[29] Wu SC, Jeng S, Huang SC, Lin SM. Corneal endothelial damage after neodymium:YAG laser iridotomy. Ophthalmic Surg Lasers. 2000;31(5):411–416. PMID: 11011710. https://doi.org/10.3928/1542-8877-20000901-09

[30] Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. https://doi.org/10.1186/s41073-019-0064-8

[31] Gulati V, Pahuja S, Fan S, Toris CB. An experimental steroid responsive model of ocular inflammation in rabbits using an SLT frequency doubled Q switched Nd:YAG laser. J Ocul Pharmacol Ther. 2013;29(7):663–669. https://doi.org/10.1089/jop.2012.0223

[32] Kramer TR, Noecker RJ. Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology. 2001;108(4):773–779. https://doi.org/10.1016/S0161-6420(00)00660-6

[33] Dang Y, Waxman S, Wang C, Loewen RT, Sun M, Loewen NA. A porcine ex vivo model of pigmentary glaucoma. Sci Rep. 2018;8:5468. https://doi.org/10.1038/s41598-018-23861-x

[34] Edwards M, Cha D, Krithika S, Johnson M, Cook G, Parra EJ. Iris pigmentation as a quantitative trait: variation in populations of European, East Asian and South Asian ancestry and association with candidate gene polymorphisms. Pigment Cell Melanoma Res. 2016;29(2):141–162. https://doi.org/10.1111/pcmr.12435

[35] Devaux A, Genuer R, Peres K, Proust-Lima C. Individual dynamic prediction of clinical endpoint from large dimensional longitudinal biomarker history: a landmark approach. BMC Med Res Methodol. 2022;22:188. https://doi.org/10.1186/s12874-022-01660-3

[36] Chakraborty B, Murphy SA. Dynamic treatment regimes. Annu Rev Stat Appl. 2014;1:447–464. https://doi.org/10.1146/annurev-statistics-022513-115553

[37] Ning B, Baboolal S, Gizzi C, Nolan W. A case of secondary pigment dispersion following laser to cosmetically lighten the irises. J Glaucoma. 2022;31(2):133–135. https://doi.org/10.1097/IJG.0000000000001790

[38] Swampillai AJ, Sherman T, Garg A, Tan IJ, Lim KS. Secondary pigmentary glaucoma following cosmetic laser treatment to alter iris colour. Cont Lens Anterior Eye. 2023;46(2):101754. https://doi.org/10.1016/j.clae.2022.101754

[39] Basoglu A, Celik U. The effect of SLT laser application on iris to treat sectorial heterochromia: a promising technique. Eye Contact Lens. 2018;44(Suppl 1):S352–S354. https://doi.org/10.1097/ICL.0000000000000374

[40] Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. https://doi.org/10.1016/j.ajo.2005.03.057

[41] Epstein DL, Freddo TF, Anderson PJ, Patterson MM, Bassett-Chu S. Experimental obstruction to aqueous outflow by pigment particles in living monkeys. Invest Ophthalmol Vis Sci. 1986;27(3):387–395. PMID: 3949467.

[42] Dang Y, Waxman S, Wang C, Shah P, Loewen RT, Loewen NA. Intraocular pressure elevation precedes a phagocytosis decline in a model of pigmentary glaucoma [version 2; peer review: 2 approved]. F1000Res. 2018;7:174. https://doi.org/10.12688/f1000research.13797.2. PMID: 29721307.

[43] Mete M. Long-Term Intraocular Pressure Dynamics After Selective Stromal Melanin Modulation: A Testable Mechanistic Framework [full manuscript]. MyLumineyes Research Papers. 2026. https://mylumineyes.com/research/papers/ssmm-iop-mechanistic-framework/

[44] Mete M. Advanced Principles of Laser Iris Depigmentation [author research synthesis; includes the Lumineyes Conceptual Fingerprint—LRS Edition]. MyLumineyes Research Archive. Updated November 2026. https://mylumineyes.com/research/scientific-analysis-laser-eye-color-change/

[45] Mete M. SSMM–IOP Research: Long-Term Intraocular Pressure Dynamics [author research-owner synthesis]. MyLumineyes Research Archive. 2026. https://mylumineyes.com/research/ssmm-iop-long-term-intraocular-pressure-dynamics/

[46] Mete M. Lumineyes™ Clinical Data: Nine Years of Longitudinal Clinical Observations [author clinical archive report]. MyLumineyes Research Archive. Updated November 2026. https://mylumineyes.com/research/laser-eye-color-change-clinical-data/

[47] Nemoto H, et al. Apoptosis inhibitor of macrophages/CD5L enhances phagocytosis in the trabecular meshwork cells and regulates ocular hypertension. J Cell Physiol. 2023. https://doi.org/10.1002/jcp.31097. PMID: 37584382.

[48] Liu KC, et al. Resident tissue macrophages maintain intraocular pressure homeostasis. Immunity. 2026;59(4):943–952.e4. https://doi.org/10.1016/j.immuni.2026.01.025. PMID: 41806829.

[49] Schuman DM, Suarez MF, Grimsrud AO, Kuhn M, Saban DR, Stamer WD, Liu KC. Intracameral puncture lowers intraocular pressure and triggers an immune response in the conventional outflow tract. Invest Ophthalmol Vis Sci. 2025;66(14):54. https://doi.org/10.1167/iovs.66.14.54. PMID: 41268981.

[50] Peles DN, Hong L, Hu DN, Ito S, Nemanich RJ, Simon JD. Human iridal stroma melanosomes of varying pheomelanin contents possess a common eumelanic outer surface. J Phys Chem B. 2009;113:11346–11351. https://doi.org/10.1021/jp904138n. PMID: 19618947.

[51] Porter KM, Epstein DL, Liton PB. Up-regulated expression of extracellular matrix remodeling genes in phagocytically challenged trabecular meshwork cells. PLoS One. 2012;7:e34792. https://doi.org/10.1371/journal.pone.0034792. PMID: 22529935.

[52] Buller C, Johnson DH, Tschumper RC. Human trabecular meshwork phagocytosis: observations in an organ culture system. Invest Ophthalmol Vis Sci. 1990;31:2156–2163. PMID: 2211012.

[53] Johnson DH, Richardson TM, Epstein DL. Trabecular meshwork recovery after phagocytic challenge. Curr Eye Res. 1989;8:1121–1130. https://doi.org/10.3109/02713688909000037. PMID: 2612200.

[54] Kizhatil K, Clark GM, Sunderland DK, Bhandari A, Horbal LJ, Balasubramanian R, John SWM. FYN regulates aqueous humor outflow and IOP through the phosphorylation of VE-CADHERIN. Nat Commun. 2025;16:51. https://doi.org/10.1038/s41467-024-55232-8. PMID: 39746990.

[55] Alvarado JA, et al. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005;89:1500–1505. https://doi.org/10.1136/bjo.2005.081307. PMID: 16234461.

[56] Bradley JMB, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000;41:422–430. PMID: 10670472.